Brazil Update

RNS Number : 2170Z
Plant Health Care PLC
09 January 2020
 

9 January 2020

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Brazil Update

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, provides the following update on trading in Brazil further to the Trading Update on 19 December 2019.

 

Plant Health Care has now received the licence to import unlimited amounts of Harpin 𝜶β into Brazil, which had been anticipated in late 2019.  This licence will allow the Company to ship product to Brazil to satisfy existing demand in sugar cane and row crops; it is anticipated that orders will be invoiced during the first quarter of 2020.

 

Demonstration trials of Harpin 𝜶β reliably give average yield increases of 20% or more in sugar cane in Brazil.  The Company currently has trials on the ground with producers and processors which grow some 3 million Ha of sugar cane; these trials will report results during the course of 2020.

 

Chris Richards, CEO of Plant Health Care said: "This import licence unblocks sales of Harpin 𝜶β to Brazil, which we had anticipated in 2019.  We are now free to explore ways of ramping up sales to sugar cane in Brazil even faster.  With more than 8 million Ha of sugar cane planted in Brazil, this is a huge opportunity for the Company."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, CEO                                                              Tel: +1 919 926 1600

 

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Dan Gee-Summons                         Tel: +44 (0) 20 7614 5900

 

 

 

Company website: www.planthealthcare.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUWOKRRVUARAR
UK 100

Latest directors dealings